An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Condition:   Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC)
Interventions:   Drug: Copanlisib;   Drug: Nivolumab
Sponsor:   Bayer
Not yet recruiting

https://ift.tt/2Pgz29P